Federal Register / Vol. 73, No. 180 / Tuesday, September 16, 2008 / Notices 53437 

Publications: 

1. UJ Buchholz et al. Chimeric bovine 

respiratory syncytial virus with 

glycoprotein gene substitutions from 

human respiratory syncytial virus 

(HRSV): effects on host range and 

evaluation as a live-attenuated HRSV 

vaccine. J Virol. 2000 Feb;74(3):1187– 

1199. 

2. A Karger et al. Recombinant bovine 

respiratory syncytial virus with 

deletions of the G or SH genes: G and 

F proteins bind heparin. J Gen Virol. 

2001 Mar;82(Pt 3):631–640. 

3. UJ Buchholz et al. Generation of 

bovine respiratory syncytial virus 

(BRSV) from cDNA: BRSV NS2 is not 

essential for virus replication in tissue 

culture, and the human RSV leader 

region acts as a functional BRSV 

genome promoter. J Virol. 1999 

Jan;73(1):251–259. 

Patent Status: 

HHS Reference No. E–178–1999/0— 

• International Patent Application 

PCT/US00/17755, which published 

as WO 2001/04335 on 09 Jan 2001 

(expired) 

• Australian Patent 784216 

• Chinese Patent 00810119.1 

• Canadian Patent Application 

2378552 

• European Patent Application 

00941756.9 

• Israeli Patent Application 147447 

• Japanese Patent Application 2001– 

509539 

• Korean Patent Application 10– 

2002–7000318 

• Mexican Patent Application 2002– 

000220 

• Brazilian Patent Application 

PI0013195–4 and 

• Chinese Patent Application 

200710167112.6 

HHS Reference No. E–178–1999/1— 

• U.S. Patent Application No. 11/ 

097,946 filed 31 Mar 2005 

HHS Reference No. E–178–1999/2— 

• U.S. Patent Application No. 10/ 

704,116 filed 07 Nov 2003 

Licensing Status: Available for 

licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIAID Office of Technology 

Development is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize attenuated live vaccines 

against respiratory syncytial virus 

(RSV). Please contact Barry Buchbinder 

at 301–594–1696 for more information. 

Dated: September 9, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–21519 Filed 9–15–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Cancer Institute Director’s 

Consumer Liaison Group. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Director’s Consumer Liaison Group. 

Date: October 14–15, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: (1) Approval of Minutes; (2) 

Report from Dr. John Niederhuber, NCI 

Director; (3) Report on the OAR; (4) Report 

from Planning & Office of Governmental & 

Congressional Relations OD/NCI; (5) Indian 

Health Service & Cancer Issues of Native 

Americans; (6) Cancer Health 

Communications; (7) Update-NCI 

Community Cancer Clinics Program; (8) 

Reports from DCLG Working Groups & 

Member Updates; (9) Public Comment; (10) 

Action Items/Conclusion. 

Place: National Institutes of Health, 

Building 31, Conference Room 6, 31 Center 

Drive, Bethesda, MD 20892. 

Contact Person: Shannon K. Bell, MSW, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 31 

Center Drive, Building 31, Room 10A30D, 

Bethesda, MD 20892, 301–451–3393. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

deainfo.nci.nih.gov/advisory/dclg/dclg.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 9, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–21499 Filed 9–15–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Cancer Institute Board of 

Scientific Advisors. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Board of Scientific Advisors. 

Date: November 6–7, 2008. 

Time: November 6, 2008, 8 a.m. to 6 p.m. 

Agenda: Director’s Report: Ongoing and 

New Business; Reports of Program Review 

Group(s); and Budget Presentation; Reports of 

Special Initiatives; RFA and RFP Concept 

Reviews; and Scientific Presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, 6th Floor, 

Conference Room 10, Bethesda, MD 20892. 

Time: November 7, 2008, 8:30 a.m. to 

12 p.m. 

Agenda: Reports of Special Initiatives; RFA 

and RFP Concept Reviews; and Scientific 

Presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, 6th Floor, 

Conference Room 10, Bethesda, MD 20892. 

Contact Person: Paulette S. Gray, PhD, 

Executive Secretary, Director, Division of 

Extramural Activities, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Rm. 8001, 

Bethesda, MD 20892, 301–496–5147, 

grayp@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 


ebenthall on PROD1PC60 with NOTICES